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Background: The Prostate Cancer Research International Active Surveillance (PRIAS) study was
initiated a decade ago to study the most optimal selection and follow-up of men on active
surveillance (AS).
Objective: We report on 10 yr of follow-up of men on AS in the PRIAS study and evaluate if criteria
used to recommend a switch to active treatment truly predict unfavorable outcome on subsequent
radical prostatectomy (RP).
Design, setting, and participants: Men with low-risk prostate cancer were included and followed
prospectively on AS. Follow-up consisted of regular prostate-specific antigen (PSA) tests, digital
rectal examinations, and biopsies. Men with Gleason >3 + 3, more than two positive biopsy cores, or
stage higher than cT2 were advised to switch to active treatment (until 2014, a PSA doubling time
[PSA DT] of 0–3 yr was also used).
Outcome measurements and statistical analysis: Reclassification rates, treatment after discontinu-
ation, and outcome on RP after discontinuing AS were reported. Regression analysis on the outcome
of RP was used to evaluate the predictive value of criteria currently used to recommend a switch to
active treatment. Kaplan-Meier and competing risk analysis were used to report discontinuation
rates over time and long-term oncologic end points.
Results and limitations: A total of 5302 men were included in PRIAS across 18 countries. Reclassifi-
cation rates remained stable on all subsequent biopsies, with 22–33% of men having either Gleason
>3 + 3 or more than two positive cores on any repeat biopsy. At 5 and 10 yr of follow-up, 52% and 73%
of men, respectively, had discontinued AS, most of them because of protocol-based reclassification. A
third of men undergoing subsequent RP had favorable pathologic tumor features (Gleason 3 + 3 and
pT2). Of the criteria used to recommend a switch to active treatment, more than two positive cores
and a PSA DT of 0–3 yr were not predictive of unfavorable pathologic outcome on RP.
Conclusions: A substantial group of men discontinued AS without subsequent unfavorable tumor
features on RP; therefore, we propose Gleason upgrading and cT3 as the only indicators for an
immediate switch to active treatment. Surrogate indicators (eg, more than two positive cores and a
fast-rising PSA) should not trigger immediate active treatment but rather further investigation to
confirm the suspicion of higher risk disease.
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The Prostate Cancer Research International Active Surveil-
lance (PRIAS) study was initiated a decade ago (2006) with
the aim of providing evidence-based recommendations on
how to select and follow men with low-risk prostate cancer
(PCa) on active surveillance (AS) [1]. Other than most single
(academic) center AS studies, the PRIAS study aims to
represent a more real-world situation with inclusions from
academic, nonacademic, and private practices across the
world, greatly increasing the generalizability of the results.
Since its introduction, the PRIAS study has developed into
the largest prospective AS study worldwide, with at present
>150 participating centers in 18 countries. Data on the first
500 study participants were reported in 2010 [2], with an
update on 2500 men in 2012 [3].
We report on >5000 men followed on AS in the PRIAS
study to date, and we specifically evaluate the criteria used
to recommend a switch to active treatment by assessing
their ability to predict outcome on radical prostatectomy
(RP) in men discontinuing AS.
2. Methods
All centers prospectively enter data on inclusion, and they
follow up through the PRIAS Web site (www.prias-project.
org) that automatically provides recommendations on
follow-up [1]. The original criteria for inclusion are Gleason
score 3 + 3, stage not higher than cT2c, PSA 10 ng/ml,
two or fewer cores positive for PCa, prostate-specific antigen
(PSA) density 0.2 ng/ml per cubic centimeter, and fitness
for curative treatment. In 2012 and 2015, inclusion criteria
were adapted to include minimal Gleason 3 + 4 and
accommodate changes in the number of positive cores
caused by biopsies targeted by magnetic resonance imaging
(MRI) or saturation biopsies (all changes made to the study
protocol are summarized in Table 1). No minimum numberTable 1 – Changes made and proposed to the PRIAS study protocol
Year 2012 2015
Change to Inclusion criteria Inclusion criteria Follow-
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MRI = magnetic resonance imaging; PSA = prostate-specific antigen; PSA DT = proof biopsy cores is required, but based on prostate volume the
following is advised:<40 cm3: 8 cores; 40–60 cm3: 10 cores;
and >60 cm3: 12 cores (>80% complied).
In the first 2 yr of follow-up, a PSA test is scheduled every
3 mo, and a digital rectal examination (DRE) is scheduled
every 6 mo. Thereafter, PSA is measured every 6 mo, and
DRE is performed once yearly. Standard repeat biopsies are
scheduled 1, 4, 7, and 10 yr after diagnosis and subsequently
every 5 yr. Yearly biopsies are only recommended if PSA
doubling time (PSA DT) is between 0 and 10 yr. A bone scan
is recommended if the PSA level is 20 ng/ml.
Criteria used to recommend a switch to active treatment
are Gleason >3 + 3, more than two positive cores, and stage
higher than cT2. A PSA DT between 0 and 3 yr (if at least
four PSA values are available) was used to recommend
immediate active treatment until the end of 2014 but
was dropped afterward due to the low number of men
complying with this recommendation and the high
percentage of men receiving unnecessary treatment, as
described in a recent publication [4]. Criteria used to
recommend a switch to active treatment were adapted
for those included with Gleason 3 + 4 and more than two
cores based on MRI or saturation biopsies (Table 1).
More information on the follow-up schedule and a
flowchart of the current follow-up protocol can be found
online (www.prias-project.org). Follow-up for the current
analysis ended in November 2015.2.1. Statistical analysis
Descriptive statistics were used to report baseline char-
acteristics, reclassification rates on subsequent biopsies,
treatment after discontinuation, and outcome on RP after
discontinuing AS. Pathologic outcome on RP was divided in
three categories: favorable pathology (Gleason 3 + 3 and
pT2), intermediate pathology (Gleason 3 + 4 and pT2), and
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Fig. 1 – Reclassification rates on subsequent repeat biopsies during follow-up.
Pbx = repeat biopsy.
Table 2 – Characteristics at diagnosis of all men included in the
PRIAS study
Characteristic Result
Age, yr 65.9 (61.0–70.4)
PSA, ng/ml 5.7 (4.5–7.1)
Prostate volume, cm3 45 (35–59)
PSA density, ng/ml per cm3 0.13 (0.09–0.16)
No. of biopsy cores 12 (10–12)





3 + 3 5271 (99)












IQR = interquartile range; PSA = prostate-specific antigen.
Data shown as median (IQR) or n (%).
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metastatic potential of men with Gleason 3 + 3 organ-
confined disease on RP [5–7].
Multinomial logistic regression analysis was used to
evaluate the predictive value of criteria used to recommend
a switch to active treatment (Gleason>3 + 3, more than two
positive cores, PSA DT between 0 and 3 yr) on pathologic RP
outcome. The predictive value of cT3 could not be assessed
due to the low number of men with this characteristic.
Corrections were made for clinical characteristics at the
time of switching to active treatment (age and PSA).
Kaplan-Meier and competing risk analysis were used to
report discontinuation rates over time, (PCa) mortality, and
a combined end point of biochemical recurrence (BCR;
defined as a PSA level 0.2 ng/ml after RP or a PSA level
2.0 ng/ml above the nadir after radiation therapy [RT]) or
local recurrence after active treatment (either RP or RT),
metastasis, and PCa death, whichever occurred first for all
men included.
Separate analyses were done for all men included and for
men fulfilling the original inclusion criteria, except for the
multinomial analysis that was only done in men fulfilling
the original inclusion criteria. For analysis, SPSS for
Windows v.21.0 (IBM Corp., Armonk, NY, USA) and the
survival package of R (R Foundation for Statistical Comput-
ing, Vienna, Austria) were used.
3. Results
A total of 5302 men were included and followed prospec-
tively on AS in the PRIAS study across 18 countries
(Supplementary Fig. 1). Of these men, 622 were followedon AS>5 yr and 107 were followed for>7.5 yr. At diagnosis,
the median age was 65.9 yr, the median PSA was 5.7 ng/ml,
and most men had one positive biopsy core (69%) with
Gleason 3 + 3 (99%) and a clinical stage T1c (88%) (Table 2).
A total of 216 men (4%) did not fully comply with the
Table 3 – Discontinuation and treatment after discontinuation
RP RT HT WW Other Unknown Died/lost to FU Total
Non–protocol based
Anxiety/Patient request (%) 52 (29) 32 (18) 2 (1) – 2 (1) 89 (50) – 177 (100)
Other/Unknown (%) 108 (45) 78 (32) 2 (1) – 27 (11) 27 (11) – 242 (100)
Switch to WW – – – 134 (100) – – – 134 (100)
Died – – – – – – 57 (100) 57 (100)
Lost to FU – – – – – – 56 (100) 56 (100)
Protocol based (%)* 496 (45) 419 (38) 29 (3) 30 (3) 30 (3) 98 (9) – 1102 (100)
Total (%) 656 (37) 529 (30) 33 (2) 164 (9) 59 (3) 214 (12) 113 (6) 1768 (100)
FU = follow-up; HT = hormonal therapy; PSA DT = prostate-specific antigen doubling time; RP = radical prostatectomy; RT = radiation therapy; WW = watchful
waiting.
* Gleason >3 + 3, >2 cores positive, stage higher than cT2, or PSA DT 0–3 yr.
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because the PRIAS Web site currently allows off-protocol
inclusions). Subanalyses in men fulfilling the original
inclusion criteria yielded identical results and thus are
not presented.
During follow-up, 3379 men received at least one repeat
biopsy; 1077 men received two biopsies, 282 men had
three biopsies, 68 men had four biopsies, and 15 men had
five biopsies. Reclassification rates remained stable on all
subsequent biopsies, with 13–16% of men having Gleason
>3 + 3, 16–27% of men having more than two cores positive
for PCa, and 22–33% of men having either Gleason >3 + 3 or
more than two positive cores (Fig. 1).
A total of 1768 of the 5302 men discontinued AS until
the end of follow-up, most of them (n = 1102) because of
protocol-based reclassification. Treatment after discontin-
uation was RP or RT in 67% of men, and only 3% received
hormonal therapy as primary treatment (Table 3). There
were no differences in tumor characteristics (PSA, PSA DT,
Gleason, and number of positive cores on last biopsy)
between men switching to RP or RT, but the latter had a 2-yr
higher median age at the time of discontinuation (67 vs
69 yr, respectively; p < 0.001).
[(Fig._2)TD$FIG]Fig. 2 – Discontinuation of active surveillance over time, stratified by reason fo
FU = follow-up; PSA DT = prostate-specific antigen doubling time; WW = watchfAfter 5 and 10 yr of follow-up, respectively, 48% and 27%
of men were still on AS, 34% and 41% discontinued because
of protocol-based reclassification, 5% and 5% discontinued
due to anxiety/patient request (without having reclassifi-
cation, anxiety and patient request were equally distribut-
ed), 5% and 15% switched to watchful waiting (WW) or died
of another cause (without having reclassification), and 8%
and 12% discontinued for other reasons (without having
reclassification) (Fig. 2).
Pathology data for 360 men receiving RP after disconti-
nuing AS were available for analysis. For men who switched
to RP due to anxiety, 13 (57%) had a favorable pathologic
outcome, 6 (26%) had an intermediate pathologic outcome,
and 4 (17%) had an unfavorable pathologic outcome.
For men who switched to RP because of protocol-based
reclassification, 82 (30%) had a favorable pathologic
outcome, 85 (34%) had an intermediate pathologic outcome,
and 100 (36%) had an unfavorable pathologic outcome.
Overall, pT3a, pT3b, pT4, Gleason 8, and N1 were found in
61, 13, 2, 14, and 1 (of 119 men receiving a lymph node
dissection), respectively. Large differences in the distribu-
tion of outcomes were observed between different proto-
col-based reasons to discontinue AS (Table 4). On regressionr discontinuation.
ul waiting.
Table 5 – Predictors of intermediate (Gleason 3 + 4 and pT2) and unfavorable outcome (Gleason I4 + 3 or IpT3) on radical prostatectomy*,y
Intermediate Unfavorable
OR (95% CI) p value OR (95% CI) p value
Age at discontinuation, yr 1.04 (0.99–1.09) 0.136 1.04 (0.99–1.09) 0.101
Last PSA, ng/ml 0.93 (0.85–1.03) 0.146 1.00 (0.91–1.09) 0.925
PSA DT 0–3 yr 0.71 (0.37–1.38) 0.312 1.44 (0.79–2.63) 0.230
No. of positive cores >2 on last biopsy 1.50 (0.83–2.70) 0.183 1.37 (0.78–2.43) 0.274
Gleason >6 on last biopsy 7.44 (3.68–15.06) <0.001 6.12 (3.04–12.32) <0.001
CI = confidence interval; OR = odds ratio; PSA = prostate-specific antigen; PSA DT = prostate-specific antigen doubling time; RP = radical prostatectomy.
* Only men fulfilling the original inclusion criteria were included; n = 347.
y OR as compared with favorable RP outcome.
Table 4 – Outcome on radical prostatectomy after discontinuing active surveillance
Favorable
(Gleason 3 + 3 and pT2)
Intermediate
(Gleason 3 + 4 and pT2)
Unfavorable
(Gleason 4 + 3 or pT3)
Total
Non–protocol based, n (%)
Anxiety/Patient request 13 (57) 6 (26) 4 (17) 23 (100)
Other/Unknown 28 (47) 12 (20) 20 (33) 60 (100)
Protocol based, n (%)
1. Only Gleason >3 + 3
Gleason 3 + 4 7 (27) 15 (58) 4 (15) 26 (100)
Gleason 4 + 3 1 (7) 3 (21) 10 (71) 14 (100)
2. Only >2 cores positive 28 (41) 22 (32) 18 (26) 68 (100)
3. Only PSA DT 0–3 yr 24 (46) 9 (17) 19 (37) 52 (100)
4. Only cT3 1 (50) – 1 (50) 2 (100)
Combination 1 + 2 1 (2) 28 (55) 22 (43) 51 (100)
Combination 1 + 3 2 (18) 3 (27) 6 (55) 11 (100)
Combination 2 + 3 16 (50) 6 (19) 10 (31) 32 (100)
Combination 1 + 2 + 3 2 (10) 9 (43) 10 (48) 21 (100)
Total, n (%) 123 (34) 113 (31) 124 (34) 360 (100)
PSA DT = PSA doubling time.
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statistically significant predictor of intermediate or unfa-
vorable pathologic outcome on RP (Table 5).
Until the end of follow-up of all men included, 30 men
had biochemical recurrence (BCR) after active treatment
(either RP or RT), 10 men had local recurrence, 8 developed
metastasis, and 1 died of PCa, resulting in 98% and 94% of all
men included to be free of BCR, local recurrence, metastasis,
and PCa death at 5 and 10 yr after diagnosis, respectively
(Supplementary Fig. 2). Other-cause mortality and disease-
specific mortality for all men included were 3% and <1%,
respectively, at 5 yr after diagnosis and 11% and <1%,
respectively, at 10 yr after diagnosis (Supplementary Fig. 3).
4. Discussion
AS aims to reduce the overtreatment of tumors that are very
unlikely to cause symptoms if left untreated. Nevertheless,
the possibility remains that tumors with initial low-risk
features will turn out not to be indolent and develop into
lethal disease. AS is supposed to filter out these men
selectively as soon as possible while avoiding invasive
treatment in most cases that prove to be truly indolent. The
first part of the aim of AS seems partially fulfilled. In the
Toronto and Johns Hopkins cohorts of men on AS, very low
PCa mortality and metastasis rates were observed, compa-
rable with those after more invasive treatment (RP and RT)[8,9]. Although only a few men were followed >10 yr in the
current analysis, results support the safety of AS. PCa
mortality was <1%, and a combined end point of adverse
outcome (BCR, local recurrence, metastasis, or PCa death)
was observed in only 6% of men 10 yr from diagnosis.
In the current analysis, we found only 50% of men to still
be on AS after 5 yr of follow-up and approximately only 25%
after 10 yr of follow-up, lower than reported by other AS
studies [8–10]. Some of these differences could be explained
by the setup of the PRIAS study, which is not a strictly
controlled single academic center study but instead tries to
represent a real-world situation (eg, resulting in more men
switching to active treatment without a clear protocol-
based reason or more men switching to WW). Nevertheless,
even if accounting for the 15% of men stopping AS because
of a switch to WW or other cause mortality, a substantial
number of men (60% of the initial cohort) received a form of
active treatment after 10 yr of follow-up.
This finding, together with the observation that a third of
men still had a favorable pathologic outcome on RP,
indicates that the criteria used to recommend a switch to
active treatment are far from optimal. On regression
analysis, the only statistically significant predictor of
intermediate or unfavorable pathologic outcome on RP
was a Gleason score>6 on last biopsy. In men who switched
to RP due to more than two cores positive on last biopsy and
in men with a PSA DT of 0–3 yr, the rates having favorable
E U R O P E A N U R O L O G Y 7 0 ( 2 0 1 6 ) 9 5 4 – 9 6 0 959pathologic outcome were close to 50%, although the rates of
unfavorable pathologic outcome were higher than in men
who switched to active treatment without a protocol-based
recommendation. Both of these protocol-based indications
seem to increase the risk of unfavorable pathologic outcome
but are not specific enough to trigger an immediate switch
to active treatment. Importantly, PSA DT 0–3 and more than
two cores positive with PCa together are responsible for
>50% of all recommendations to switch to active treatment.
To achieve a higher rate of men who continue AS while
selectively identifying those with unfavorable disease, we
propose a change of protocol for the PRIAS study. Instead of
an immediate switch to active treatment if more than two
cores are positive, men should receive further investigation
to confirm higher risk disease. Because MRI is shown to have
a negative predictive value for Gleason upgrading very close
to 100% in men on AS [11–13], it currently seems the best
method to exclude the presence of a higher Gleason score. If
the MRI is negative, AS can be continued; if a lesion is
present, targeted biopsies should confirm Gleason upgrading
before a switch to active treatment is advised. MRI with
targeted biopsies in men with increased risk is expected
to detect most of the men with truly unfavorable tumor
characteristics [11,14]. This modification is in line with the
recently changed recommendation in men with a PSA DT of
0–3 yr and with the changed criteria that allow inclusion of
any number of positive cores if an MRI with targeted biopsies
is done [4]. Gleason >6 and cT3 will thus remain the only
indicators for an immediate switch to active treatment. It is
estimated, based on the data in this paper, that because of
the suggested protocol change instead of 43 of 100 men,
64 of 100 men could have stayed on AS after three repeat
biopsies.
In the (near) future, MRI might even be able to replace
systematic repeat biopsies altogether. Systematic biopsies
currently appear one of the largest burdens for men on AS
[4,15,16], and in fact they are redundant in three-quarters of
men because they do not show reclassification (Fig. 1). But
before we can definitively adopt such a change, we must
collect enough data on men with a negative MRI who
simultaneously received systematic biopsies. We issue a
plea for increased inclusion of men in the PRIAS MRI side
study (www.prias-project.org) to further establish the
negative predictive value of MRI in men on AS. If confirmed,
many systematic biopsies can be replaced by less invasive
imaging.
Some changes to the number and frequency of follow-up
visits remain to be discussed. PSA testing is done regularly
and is used to calculate PSA DT (used to recommend more
frequent biopsies) and a bone scan (if PSA >20 ng/ml). We
previously showed data from the PRIAS study indicating that
after 4 yr of follow-up, both a change in PSA DT triggering a
biopsy and an absolute PSA >20 occurred very infrequently
[17]. Clinical utility was low (all bone scans were negative
and biopsies were only advanced by 6 mo). It was concluded
that PSA testing can be reduced to once yearly after 4 yr of
follow-up.
It is sometimes suggested to use an absolute PSA value
(eg,>20 ng/ml) to recommend a switch to active treatment.The PRIAS study did not include such a recommendation
because it was felt that once included with a PSA10 ng/ml,
the PSA value could only rise slowly (in which case benign
prostatic hyperplasia might be a more likely cause) or fast,
but then PSA DT would trigger further investigation with
biopsies to exclude rapid tumor development as its cause.
The analysis presented in Table 5 confirms that this initial
assumption is now justified because the absolute PSA value
does not show a positive correlation with RP outcome
within the current follow-up protocol that includes regular
repeat biopsies and additional biopsies in the case of a fast
rising PSA. We therefore do not recommend an absolute PSA
cut-off to discontinue AS.
Because reclassification on DRE only occurred in 10 men
(<1% of all reclassifications), one could also argue for
reducing the number of DREs, for example, performing a
DRE only at the time of a biopsy, although the potential
benefit of reducing this relative inexpensive and easy-to-
perform test could be questioned. The largest benefit should
come from individualizing the frequency of repeat biopsies
(or in the future possibly MRIs). Currently we individualize
the biopsy frequency only based on the PSA DT; however,
several other predictors of reclassification were specified
(eg, PSA density, the number of positive biopsy cores, and
time since last biopsy) [3,4,18,19]. Risk prediction models
were already developed and should be validated and
updated in several cohorts to prolong the time to next
biopsy in men with a low risk of reclassification and
increase the frequency in men with high risk [19]. In the
future, these models can be supplemented by newly
validated markers predictive of outcome [20].
Such models can also be used to assist in the timing of
when to stop AS and switch to WW. Simultaneous
predictions of life expectancy and time until symptoms
from a low-risk tumor left untreated are needed. This is one
of the topics of the Movember-GAP3 project [21], which
combines most of the worldwide available AS cohorts
including the PRIAS study.
Criticisms of the current analysis are that follow-up data
of men who discontinued AS, including outcome of RP, were
missing in several cases. Although limiting the power of
some of the analyses, there was no indication of selective
reporting that could have affected the results (men with and
without RP data available did not differ in terms of age, PSA,
PSA DT, Gleason, and number of positive cores on last
biopsy). Longer follow-up would more firmly establish the
low rates of metastasis and PCa deaths.
5. Conclusions
After a decade of AS in the PRIAS study, criteria used to
recommend a switch to active treatment do not seem
selective enough to avoid unnecessary switches to active
treatment. A substantial proportion of men abandoning AS
based on the advice of a protocol do not have unfavorable
features after RP. We propose Gleason score upgrading or
cT3 on DRE as the only reasons for a direct switch to active
treatment. Other factors, such as more than two positive
biopsy cores and fast-rising PSA, should first trigger
E U R O P E A N U R O L O G Y 7 0 ( 2 0 1 6 ) 9 5 4 – 9 6 0960further investigation to confirm the suspicion of higher
risk disease.
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